An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial
Latest Information Update: 26 Sep 2024
At a glance
- Drugs Inclacumab (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions
- Acronyms THRIVE-133 OLE
- Sponsors Global Blood Therapeutics; Pfizer
- 29 May 2024 Planned End Date changed from 15 Nov 2028 to 4 Nov 2028.
- 29 May 2024 Planned primary completion date changed from 15 Nov 2028 to 4 Nov 2028.
- 29 May 2024 Status changed from recruiting to active, no longer recruiting.